ERBB2 and cancer: Recent reports demonstrated that a significant number (between 45% and 55%) of tumors that were previously categorized as HER2-negative cancers are actually HER2-low and should be considered as a separate entity because they exhibit different characteristics than HER2-negative tumors [17, 18].